Featured Research

from universities, journals, and other organizations

Fall Babies: Born To Wheeze?

Date:
November 24, 2008
Source:
American Thoracic Society
Summary:
It is said that timing is everything and that certainly appears to be true for autumn infants. Children who are born four months before the height of cold and flu season have a greater risk of developing childhood asthma than children born at any other time of year, according to new research.

It is said that timing is everything, and that certainly appears to be true for autumn infants. Children who are born four months before the height of cold and flu season have a greater risk of developing childhood asthma than children born at any other time of year, according to new research.

The study analyzed the birth and medical records of more than 95,000 children and their mothers in Tennessee to determine whether date of birth in relationship to the peak in winter respiratory viruses posed a higher risk for developing early childhood asthma. They found that while having clinically significant bronchiolitis at any age during infancy was associated with an increased risk of childhood asthma, for autumn babies, that risk was the greatest.

"Infant age at the winter virus peak following birth independently predicts asthma development, with the highest risk being for infants born approximately four months prior to the peak, which is represented by birth in the fall months in the Northern hemisphere. Birth during this time conferred a nearly 30 percent increase in odds of developing asthma," said Tina V. Hartert, M.D., M.P.H., associate professor of medicine and director of the center for Asthma Research at Vanderbilt University, and principal investigator of the study.

The study demonstrated for the first time that timing of birth in relationship to the peak in winter virus activity independently predicts asthma development.

The researchers propose two non-mutually exclusive possible reasons for the link: One, that there is a genetic susceptibility common to both bronchiolitis and the development of asthma; and two, that an environmental exposure such as winter viral infection causes asthma.

"The risk of progressing from bronchiolitis to asthma is almost certainly influenced by genetic factors," wrote Dr. Hartert. "However, if this association were due only to genetic factors, there would be a seasonal effect on infection but not on asthma…Instead we have shown that there is variation in the risk of developing asthma by the timing of birth in relationship to the winter virus peak for each year studied. This supports a causal relationship of childhood asthma with the winter virus peak after birth."

Unfortunately, predicting the peak of winter virus season is difficult—it can vary by up to ten weeks a year, and Dr. Hartert notes that avoiding winter virus infection would be nearly impossible—70 percent of infants are infected in their first year of life—but that for families whose infants are at high risk for developing asthma, there are a number of ways to reduce the risks associated with birth timing, including avoiding infection through administration of a vaccine or immunoprophylaxis or timing of birth in the spring months. These strategies hold the hope for asthma prevention, however, these interventions first need to be studied.

"Prospective trials with antiviral strategies, including potential new vaccines targeting [respiratory viruses] in selected populations at risk should give us better understanding of the role of viral infections in early life in the causation of childhood asthma," wrote Renato T. Stein, M.D., Ph.D., of the Pontifνcia Universidade Catσlica in Porto Alegre, Brazil in the accompanying editorial.

Currently no effective primary and secondary asthma prevention measures exits, noted Dr. Hastert. "The next critical step is support for studies designed to determine whether prevention of the ubiquitous infections during infancy prevents childhood asthma."


Story Source:

The above story is based on materials provided by American Thoracic Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wu et al. Evidence of a Causal Role of Winter Virus Infection during Infancy in Early Childhood Asthma. American Journal of Respiratory and Critical Care Medicine, December 2008; 178 (11): 1123 DOI: 10.1164/rccm.200804-579OC

Cite This Page:

American Thoracic Society. "Fall Babies: Born To Wheeze?." ScienceDaily. ScienceDaily, 24 November 2008. <www.sciencedaily.com/releases/2008/11/081121080825.htm>.
American Thoracic Society. (2008, November 24). Fall Babies: Born To Wheeze?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/11/081121080825.htm
American Thoracic Society. "Fall Babies: Born To Wheeze?." ScienceDaily. www.sciencedaily.com/releases/2008/11/081121080825.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins